Biogena Group Invest's Underutilised Factories Back €150 Million Revenue Target as Group Overhaul Advances

Biogena Group Invest hits €4.70 52-week high, up 59% YTD. Plants run at under 25% capacity, allowing potential revenue quadruple to €500M. Holding company IPO in August, merger pending.

The Austrian micronutrient specialist Biogena Group Invest has seen its stock surge to a new 52-week high of €4.70, a 59% year-to-date gain fuelled by a sweeping corporate restructuring. Yet behind the price action lies a more fundamental story: the company's manufacturing plants in Koppl and Liefering are running at less than a quarter of their capacity, giving it the theoretical ability to nearly quadruple revenue to €500 million without major capital spending on new facilities. In the most recent financial year, the group generated revenue of €124.9 million and EBITDA of €19.1 million.

The restructuring revolves around Biogena Good Vibes AG, the future parent company, which is currently raising up to €25 million through a capital increase. The subscription period is expected to run until the end of July, after which the holding entity plans to list on the Direct Market Plus segment of the Vienna Stock Exchange in August. Management has confirmed that a merger of Biogena Good Vibes with the already-listed Biogena Group Invest is under consideration, aimed at creating a leaner capital market structure. No decision on the exchange ratio or a definitive timeline has been announced, leaving Group Invest shareholders in the dark about the terms of any eventual combination.

On the operational front, Germany is being touted as the group's biggest growth opportunity. CEO Albert Schmidbauer has identified the country as the "greatest growth chance" for Biogena, and the company is investing in its webshop and trialling new retail concepts. Management has set a group revenue target of roughly €150 million for the 2026 financial year. With its factories running at well under 25% utilisation, the group has plenty of headroom to expand output without heavy expenditure on basic infrastructure — instead, capital is being directed toward process improvements and logistics for international markets.

The stock's recent momentum is reflected in its technical indicators. The share price sits almost 29% above its 50-day moving average and nearly 50% above the 200-day line. The relative strength index stands at 64.8, signalling a strong uptrend that has not yet entered overbought territory. However, with a market capitalisation of just €17.72 million and annualised volatility exceeding 82%, the stock remains highly sensitive to news flow, and even minor developments can trigger outsized swings.

Two key dates now shape the near-term outlook. The holding company's capital increase subscription closes at the end of July, and the IPO of Biogena Good Vibes is slated for August. Only after that debut will the market get clarity on the timing and exchange ratio for a potential merger with Biogena Group Invest, giving existing shareholders a clearer picture of how their stakes would be treated in the simplified structure.